Navigation Links
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR

e myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the further development and potential safety, efficacy and commercialization of Kosan's product candidates; and initiations of clinical trials and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of Kosan's product candidates, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; and other risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2006 and ot
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)... Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... development of its lead molecule, Anatabine Citrate, in ... Quotient Clinical, The Translational Pharmaceutics Company, based in the ... its early development programs. The Company expects ... end of the third quarter with the Medicines Healthcare ...
(Date:7/31/2014)... , July 31, 2014 Touro University ... has been selected as the recipient of a $150,000 ... will allow the University to increase research and classroom ... creating state-of-the-art technology for the study of health sciences, ... the diverse needs and interests of our students," said ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
(Date:7/31/2014)... July 31, 2014 Ce-Classes.com has announced ... course for healthcare professionals, a Systematic Review of ... material published in the International Journal of Clinical and ... in response to a need to have accurate information ... the best treatment possible. The material provides a ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
... type of disease, that requires insulin injections daily. Researchers ... this disease. Some medical research centers in the U.S. ... I diabetes by transplanting insulin-producing islet cells combined with ... live normal lives without insulin. , ...
... come up with a new technique of removing cancerous ... their hands and a special camera and instuments. This ... in significantly less time than the standard laproscopic procedure. ... of the American Urological Association by surgeons from the ...
... new gene which has the ability to slow down ... millions of people each year, and luckily tthe discovery ... the cancer of the colon, prostate,pancreas,brain and bowel. ... to stunt the cancer by starving the tumour ...
... from Mayo Clinic brings more choice in eating heath food// ... into any weight loss diets that restrict choices in food. ... the report that talks of sustainable eating habits that help ... weight requires a long-term commitment to making lifestyle changes. However, ...
... Researchers from UCLA had reported in the recent issue ... sleep suffer from loss of brain cells due to ... apnea, the person stops breathing during the sleep when ... in the brain as preB?tzinger complex (preB?tC), which is ...
... and its function has always left man dazzled for ... key factors// have been identified that could answer the ... babies and hence help treat prematurity. ,Identification ... brain damage repair in neurological diseases like multiple sclerosis ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Making operation and recovery time shorter 2Health News:New Healthy Weight Program Makes Healthy Eating More Interesting 2Health News:Sleep Apnea Related To Death And Loss Of Brain Cells 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
... Final Flexion Wraps restore full PIP joint ... when lost due to arthritic changes. Unparalleled ... material hugs the finger to prevent slipping ... motion. One size. Sold in packages of ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... braces are designed to provide comfortable stabilization ... and versatile, ROM braces are an easy ... The braces are extremely patient-friendly, too. , ... hinges that allow you to restrict extension ...
Medicine Products: